BioCatalyst

HDM1002 100 mg, HDM1002 200 mg, HDM1002 400 mg, Dapagliflozin (DAPA) — catalyst calendar

1 verified catalyst event(s) referencing HDM1002 100 mg, HDM1002 200 mg, HDM1002 400 mg, Dapagliflozin (DAPA), each linked to its official source. Verified as of 2026-10-20.

Upcoming

DateEventCompanyDrugOfficial source & verification
2027-02-16
in 4mo
ESTIMATED
 READOUT
A Phase 3 Study to Evaluate Efficacy and Safety of HDM1002 Tablets in Adults Wit
Phase 3 · Type 2 Diabetes
 Hangzhou Zhongmei Huadong Pharmace HDM1002 100 mg, HDM1002 200 mg, HDM1002 ClinicalTrials.gov ↗
✓ Source-checked 2026-10-20
Sponsor-projected date — can change
Disclaimer. Bio Catalyst Calendar is a public-events data calendar. Every date is sourced and linked to an official record (ClinicalTrials.gov, FDA / Federal Register, openFDA). It is scheduling and reference data only — NOT investment advice, a recommendation, or a buy/sell signal. Dates set by sponsors and the FDA can change; always confirm against the linked official source.